Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice.
In clinical settings, Lactobacillus johnsonii La1 administration has been reported to have a favorable effect on Helicobacter pylori-associated gastritis, although the mechanism remains unclear. We administered, continuously through the water supply, live La1 to H. pylori-infected C57BL/6 mice and followed colonization, the development of H. pylori-associated gastritis in the lamina propria, and the levels of proinflammatory chemokines macrophage inflammatory protein 2 (MIP-2) and keratinocyte-derived cytokine (KC) in the serum and gastric tissue over a period of 3 months. We documented a significant attenuation in both lymphocytic (P=0.038) and neutrophilic (P=0.003) inflammatory infiltration in the lamina propria as well as in the circulating levels of anti-H. pylori immunoglobulin G antibodies (P=0.003), although we did not observe a suppressive effect of La1 on H. pylori colonizing numbers. Other lactobacilli, such as L. amylovorus DCE 471 and L. acidophilus IBB 801, did not attenuate H. pylori-associated gastritis to the same extent. MIP-2 serum levels were distinctly reduced during the early stages of H. pylori infection in the La1-treated animals, as were gastric mucosal levels of MIP-2 and KC. Finally, we also observed a significant reduction (P=0.046) in H. pylori-induced interleukin-8 secretion by human adenocarcinoma AGS cells in vitro in the presence of neutralized (pH 6.8) La1 spent culture supernatants, without concomitant loss of H. pylori viability. These observations suggest that during the early infection stages, administration of La1 can attenuate H. pylori-induced gastritis in vivo, possibly by reducing proinflammatory chemotactic signals responsible for the recruitment of lymphocytes and neutrophils in the lamina propria.
Sgouras
Dionyssios N
DN
Dept. of Medical Microbiology, Institut Pasteur Hellenique, 127 Vas. Sofias Avenue, 115 21 Athens, Greece. sgouras@pasteur.gr
Panayotopoulou
Effrosini G
EG
Martinez-Gonzalez
Beatriz
B
Petraki
Kalliopi
K
Michopoulos
Spyros
S
Mentis
Andreas
A
D000818:Animals; D000907:Antibodies, Bacterial / Q000502:physiology; D015169:Colony Count, Microbial; D005500:Follow-Up Studies; D005753:Gastric Mucosa / Q000276:immunology* / Q000382:microbiology; D005756:Gastritis / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D016481:Helicobacter Infections / Q000276:immunology / Q000628:therapy*; D016480:Helicobacter pylori / Q000276:immunology; D007074:Immunoglobulin G / Q000502:physiology; D016209:Interleukin-8 / Q000378:metabolism; D007778:Lactobacillus; D008214:Lymphocytes / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D020556:Neutrophil Infiltration
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D016209:Interleukin-8